- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 02.04. | Immunovant eye drug flunks Phase 3 studies; Beam sickle cell data published in NEJM | ||
| 01.04. | Biogen, on the heels of a $5.6B buyout, turns its sights to early-stage assets | ||
| 01.04. | FDA approves Lilly obesity pill, triggering battle with Novo Nordisk | ||
| 01.04. | Ambrosia adds a megaround for obesity drugs | ||
| 01.04. | A 'hijacked plane': CDC, under RFK Jr.'s influence, trades science for dogma | ||
| 01.04. | FDA, after turbulent year, leaves drugmakers guessing on its direction | ||
| 31.03. | Lilly beefs up neuroscience pipeline with $6.3B Centessa buyout | ||
| 31.03. | Biogen, with $5.6B Apellis buy, builds out immunology offerings | ||
| 31.03. | Viridian tumbles on positive data for key eye drug prospect | ||
| 31.03. | Merck strikes deal with antibody discovery startup | ||
| 31.03. | Biotech IPOs stayed at slow pace, but grew larger in the first quarter of 2026 | ||
| 30.03. | Blackstone closes $6.3B fund for life sciences investing | ||
| 30.03. | United rises on IPF data; Biogen scores positive lupus data and an approval | ||
| 30.03. | Lilly's AI commitment expands through deal with Insilico | ||
| 30.03. | Sanofi eczema drug weighed down by mixed results, safety concerns | ||
| 30.03. | Obesity drugmaker Kailera plans an IPO | ||
| 30.03. | Trustworthy AI in clinical oversight | ||
| 27.03. | Otsuka picks up PTSD drug with $700M Transcend buy | ||
| 27.03. | AstraZeneca lung drug gets 'surprise' win in COPD trials | ||
| 27.03. | Novartis targets Xolair successor in buyout of startup Excellergy | ||
| 27.03. | Rocket gene therapy cleared by FDA for rare immune disorder | ||
| 26.03. | Merck's deal for Terns sparks debate over a possible biotech bidding war | ||
| 26.03. | Wave crashes on obesity drug update; Kodiak's reboot pays dividends | ||
| 26.03. | FDA clears Denali drug in 'clear step' for rare disease biotechs | ||
| 25.03. | Maze tumbles on positive data for kidney disease drug |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.